Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Keech A, et al. Among authors: scott r. Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2. Lancet. 2005. PMID: 16310551 Clinical Trial.
Correction to the FIELD study report.
Keech A, Simes J, Barter P, Best J, Scott R, Taskinen MR; FIELD Management Committee. Keech A, et al. Among authors: scott r. Lancet. 2006 Oct 21;368(9545):1415. doi: 10.1016/S0140-6736(06)69594-9. Lancet. 2006. PMID: 17055933 No abstract available.
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Scott R, et al. Diabetes Care. 2009 Mar;32(3):493-8. doi: 10.2337/dc08-1543. Epub 2008 Nov 4. Diabetes Care. 2009. PMID: 18984774 Free PMC article. Clinical Trial.
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.
Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Davis TM, et al. Among authors: scott rs. Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4. Diabetologia. 2011. PMID: 21052978 Clinical Trial.
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Cannon CP, et al. N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17. N Engl J Med. 2010. PMID: 21082868 Free article. Clinical Trial.
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.
Scott R, Donoghoe M, Watts GF, O'Brien R, Pardy C, Taskinen MR, Davis TM, Colman PG, Manning P, Fulcher G, Keech AC; FIELD Study Investigators. Scott R, et al. Cardiovasc Diabetol. 2011 Nov 21;10:102. doi: 10.1186/1475-2840-10-102. Cardiovasc Diabetol. 2011. PMID: 22104275 Free PMC article. Clinical Trial.
6,554 results